Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for Chemotherapy-induced Thrombocytopenia in Solid Tumors
NCT02093325Phase 3Unknown
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Mar 2014
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Thrombocytopenia comparing Eltrombopag with Placebo (2 arms). Primary endpoint: Clinical Response Rate at 7 days. Status: unknown.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT02093325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02093325.